%0 Journal Article
%T Gender-Related Survival in Different Stages of Lung Cancer¡ªA Population Study over 20 Years
%A Gunnar Svensson
%A Sven-B£¿rje Ewers
%A Ola Ohlsson
%A H£¿kan Olsson
%J Open Journal of Internal Medicine
%P 47-58
%@ 2162-5980
%D 2014
%I Scientific Research Publishing
%R 10.4236/ojim.2014.43008
%X Introduction: Tumour stage is the most important prognostic factor in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The aim of this study was to evaluate if female gender was a prognostic factor in different tumour stages in relation to histology and given therapy. Methods: From 1989-2008, 1497 patients in eastern Scania, in southern Sweden with 202,000 inhabitants, were referred and prospectively registered. Tumour stage, performance status, lung cancer type and primary therapy were registered. Results: In NSCLC, female patients in stages 1 and 2 who were treated with surgery had a better 5-year survival rate (79.4%), compared to males (60.6%; p <span style=\"font-family:Verdana, Helvetica, Arial;line-height:18px;white-space:normal;background-color:#FFFFFF;\">=</span> 0.0004). Female patients in stage 3 with active therapy (surgery and/or radiotherapy and/or chemotherapy) had a better 5-year survival than males (20.6% vs. 10.5%, respectively, p <span style=\"font-family:Verdana, Helvetica, Arial;line-height:18px;white-space:normal;background-color:#FFFFFF;\">=</span> 0.0006). Female patients with adenocarcinoma were favourable in stages 1-3. In stage 4, there was no survival difference between females and males. In SCLC, females with limited disease (LD) and active therapy (chemotherapy <span style=\"font-family:Verdana, Helvetica, Arial;line-height:18px;white-space:normal;background-color:#FFFFFF;\">¡À</span>&nbsp;radiotherapy <span style=\"font-family:Verdana, Helvetica, Arial;line-height:18px;white-space:normal;background-color:#FFFFFF;\">¡À</span> surgery) had a higher 5-year survival rate (28%) than males (5.6%); p <span style=\"font-family:Verdana, Helvetica, Arial;line-height:18px;white-space:normal;background-color:#FFFFFF;\">=</span> 0.001. Females with extensive disease (ED) and active therapy (chemotherapy <span style=\"font-family:Verdana, Helvetica, Arial;line-height:18px;white-space:normal;background-color:#FFFFFF;\">¡À</span> radiotherapy) had a better 5-year survival (3.9%) compared to males (0.7%); p <span style=\"font-family:Verdana, Helvetica, Arial;line-height:18px;white-space:normal;background-color:#FFFFFF;\">=</span> 0.023. In multivariate analyses, patient performance status at diagnosis was also an independent prognostic factor in all tumour stages of lung cancer. Conclusions: This population-based study corroborates a female survival advantage in NSCLC stages 1-3, but not in metastatic stage 4, and this is also demonstrated for the adenocarcinoma subgroup. The study also confirms better prognosis in
%K Gender
%K Performance Status
%K Prognostic Factor
%K NSCLC (Non-Small Cell Lung Cancer)
%K SCLC (Small Cell Lung Cancer)
%K Tumour Stage
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=49530